NCT05032391View on ClinicalTrials.gov

Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 22, 2019

Primary Completion Date

September 22, 2019

Study Completion Date

October 25, 2019

Conditions
Rotavirus Infection
Interventions
BIOLOGICAL

The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)

Three times orally in a volume of 2.5 ml (1 dose)

DRUG

Placebo

Three times orally in a volume of 2.5 ml (1 dose)

Trial Locations (2)

614990

Perm State Medical University named after Academician E.A. Wagner, Perm

625023

Tyumen State Medical University, Tyumen

All Listed Sponsors
lead

Limited Liability Company Pharm Aid

OTHER

NCT05032391 - Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization | Biotech Hunter | Biotech Hunter